Orig3n, Inc., a Boston, MA-based biotechnology company developing treatments for rare and genetically inherited diseases, closed a $12.5m Series A financing. The round was co-led by Hatteras Venture Partners and Syno Capital with participation from new investor DEFTA Partners and existing investors Harris & Harris Group, Inc., LabCorp, MGC Venture Partners, KTB-KORUS Fund.
Orig3n’s science is based on Nobel Prize-winning regenerative medicine technology, and their approach will replace the trial-and-error guesswork of diagnosing and treating disease. They’ve established the world’s largest uniformly consented cell repository to better understand the cellular and molecular foundations of disease. The cells are ever-renewing and give rise to a living database of humanity they call LifeCapsule.